Outcome of implantation of a second self‐expanding valve for the treatment of residual significant aortic regurgitation. Issue 4 (15th March 2017)

• Record Type: Journal Article
• Authors: Koifman, Edward; Patel, Nirav; Weissman, Gaby; Kiramijyan, Sarkis; Didier, Romain; Torguson, Rebecca; Kumar, Sandeep; Tavil‐Shatelyan, Arpi; Ben‐Dor, Itsik; Satler, Lowell F.; Pichard, Augusto D.; Waksman, Ron
• Is Part Of: Catheterization and cardiovascular interventions. Volume 90:Issue 4(2017)
• Page Start: 673
• Page End: 679
• Publication Date: 2017-03-15
• Subjects: TAVR -- CoreValve -- paravalvular leak; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.26960
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract : Background: Residual aortic regurgitation (AR) following transcatheter aortic valve replacement (TAVR) is associated with adverse outcome. We sought to evaluate the efficacy and safety of second CoreValve (CV) implantation to treat residual AR following the initial CV deployment. Methods and Results: TAVR patients treated with a second CV due to moderate and above residual AR were compared to single device implantation. Valvular function parameters were compared at baseline, post procedure, and 30 days. Among 172 CV TAVR patients, 11 required a second device (6%) due to significant residual AR. The main differences between the groups were higher rates of low ejection fraction in patients with 2 CV implanted and higher annular diameter (27 [29–25] vs. 25 [26–24] mm, P = 0.03), requiring a larger device. Although two patients in the two CV group had high initial implantation, low implantation was similar between the groups. A second CV achieved adequate reduction in residual AR in six patients (55%), while an additional four patients had moderate residual AR. Only one remained with moderate to severe AR after 30 days follow‐up. There were no cases of peri‐procedural stroke or mortality. Conclusions: Second implantation of self‐expanding valve can successfully reduce residual significant AR following initial CV implantation and should be considered as therapeutic option for this population. © 2017 Wiley Periodicals, Inc.